# Uric Acid Lowering Trial in Youth Onset T2D

> **NCT03899883** · PHASE2 · UNKNOWN · sponsor: **University of Colorado, Denver** · enrollment: 10 (estimated)

## Conditions studied

- Diabetic Kidney Disease
- Hyperuricemia
- Diabetes
- Diabetes Mellitus, Type 2
- Type2 Diabetes
- Type 2 Diabetes Mellitus
- Diabetic Nephropathies
- Diabetes Complications

## Interventions

- **DRUG:** Pegloticase 8 MG/ML [Krystexxa]

## Key facts

- **NCT ID:** NCT03899883
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899883, "Uric Acid Lowering Trial in Youth Onset T2D". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03899883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*